Dewpoint Therapeutics is a biomolecular condensates company translating new insights about biomolecular condensates into treatments for the toughest diseases.
Dewpoint Therapeutics is the first to apply the emerging understanding of biomolecular condensates to drug discovery.
Dewpoint was founded in 2018 by Anthony Hyman and Richard Young. The company is headquartered in Boston, Massachusetts.
Dewpoint's proprietary condensates platform provides the ability to see and understand the complex interactions of biomolecular communities—and to find drugs that intervene in entirely new ways.
Dewpoint's proprietary platform uses high-throughput methods to test libraries of potential drugs for the desired effect, identifying compounds that modulate biomolecular condensates in specific diseases of immediate interest to Dewpoint and its partners.
Dewpoint's methods of investigating condensate function and targeting uses advanced AI and computer vision capabilities, proprietary data and small molecule libraries, a proprietary knowledge graph of condensates and their functional connection to disease pathology, and compounds that modulate their behavior.
Dewpoint is backed by Leaps by Bayer, ARCH Venture Partners, SoftBank Vision Fund 2, General Catalyst, Mubadala Capital, Maverick Ventures, Mirae Asset, EcoR1 Capital, Polaris Partners, Samsara BioCapital, and others. The company completed a $150M Series C round on Feb 03, 2022. This brings Dewpoint's total funding to $287M to date.